The melanoma proteoglycan: restricted expression on microspikes, a specific microdomain of the cell surface by unknown
The Melanoma Proteoglycan: Restricted Expression on 
Microspikes, a Specific Microdomain of the Cell Surface 
H. Jacques Garrigues,*5 Michael W. Lark,* Stephanie Lara,* Ingegard Hellstr~im,*¢ 
Karl Erik Hellstrtim,*¢ and Thomas N. Wight* 
* Department of Pathology, University of Washington; and ~  Oncogen, Seattle, Washington 98195. 
Address correspondence to Dr. Wight. 
Abstract.  A  cell surface chondroitin sulfate proteogly- 
can associated with human melanomas and defined by 
mAb's F24.47 and 48.7  has been characterized bio- 
chemically and localized by indirect immunogold elec- 
tron microscopy. These antibodies recognize distinct 
epitopes on the intact proteoglycan. In addition, mAb 
48.7 also recognizes an epitope on a  250,000-D  glyco- 
protein and is therefore similar to antibody 9.2.27  (de- 
scribed by Bumol, T.  E, and R.  A.  Reisfeld,  1982, 
Proc.  Natl.  Acad.  Sci.  USA.,  79:1245-1249).  Further- 
more,  it was shown that the glycosaminoglycan chains 
released by alkaline borohydride treatment of the pro- 
teoglycan recognized by mAb 48.7 had a  size of 
'~60,000  D.  Since the intact proteoglycan was esti- 
mated to be 420,000  D, there are probably three chon- 
droitin sulfate chains attached to the 250,000-D  core 
glycoprotein. Furthermore, an oligosaccharide fraction 
containing 42 %  of the 3H activity (glucosamine as 
precursor)  was isolated. 
Immunolocalization studies using whole-mount elec- 
tron microscopy revealed that the chondroitin sulfate 
proteoglycan was present almost exclusively on micro- 
spikes, a microdomain of the melanoma cell surface. 
These processes were present as  1-2-~tm structures on 
the upper cell surface and as longer (up to 20 ~tm) 
structures at the cell periphery.  Peripheral microspikes 
were involved in the initial interactions between adja- 
cent cells and formed complex footpads that made 
contact with the substratum.  Immunogold-labeled cells 
were also thin sectioned and the specific localization 
of the chondroitin sulfate proteoglycan antigen was 
quantitated. The data confirmed the results of whole- 
mount microscopy and demonstrated a  statistically 
significant association of the antigen with the 
microspike processes as compared with other areas of 
the cell surface. By using two different mAb's (48.7 
and F24.47)  that recognize epitopes on either the core 
glycoprotein or the intact proteoglycan, respectively, 
we have demonstrated that both molecules have the 
same restricted distribution at the cell surface. The 
specific localization of the antigen to microspikes at 
the cell surface suggests it may play a  role in cell-cell 
contact and cell-substratum adhesion, which could be 
important in the metastatic process. 
p 
ROTEOGLYCANS are present throughout the interstitial 
matrix  of all  tissues  and are  associated  with  such 
specialized structures as basement membranes and/or 
basal laminae (18). Furthermore, these molecules appear to 
be associated with the plasma membranes of all cells, either 
as peripheral cell surface components bound via a cell mem- 
brane receptor(s)  or intercalated within the plasma mem- 
brane itself (23, 46). 
Cell surface proteoglycans have been implicated in a vari- 
ety of cellular events,  such as proliferation (29,  35,  48), 
migration (10, 14), and adhesion (3, 5, 10, 31), and it has been 
proposed that they may influence cellular behavior by acting 
as receptors for components of the extracellular matrix and 
for various circulating molecules (23).  Proteoglycans are 
known to bind to several components of the extracellular ma- 
trix, including fibronectin (50, 53, 67), laminin (52, 65), and 
collagen (32, 53, 54), and also other proteoglycans (15). It 
has also been shown that a membrane-intercalated heparan 
sulfate proteoglycan isolated from mammary epithelial cells 
may interact with polymerized actin (47).  When this mole- 
cule  was  cross-linked  with  an  antibody,  aggregation  of 
clustered antigen was inhibited by cytochalasin D, suggesting 
that the proteoglycan was attached to the cytoskeleton (46). 
Similarly, actin and proteoglycan codistribute in  cultured 
fibroblasts and have been isolated together at focal adhesion 
sites (37, 66). It has been suggested, based on these observa- 
tions, that changes in the organization of the extracellular 
matrix  may  be  transmitted  to  the  cytoskeleton  through 
membrane-intercalated proteoglycans,  thus  ultimately  in- 
fluencing cell shape and behavior (23, 46). 
The metabolism of proteoglycans is altered in transformed 
cells, and these alterations have been implicated in the abnor- 
mal growth behavior of such cells (26).  For example, neo- 
plastic cells synthesize elevated levels of chondroitin sulfate 
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The Journal of Cell Biology, Volume 103, November 1986 1699-1710  1699 Figure  1.  Gel filtration and electrophoretic analyses of [35S]sulfate- and [3H]glucosamine-labeled melanoma antigens. Detergent-solubi- 
lized cell lysates were prepared from labeled M 2669-C1  13 and M  1477 melanoma cells. The antigens defined by mAb's 48.7 and F24.47 
were purified by affinity chromatography and analyzed on a Sepharose CL-4B column or by SDS PAGE. (a) mAb 48.7  affinity-purified 
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transformation can block proteoglycan synthesis (43). There 
is evidence that neoplastic cells can synthesize proteoglycans 
that are chemically modified, e.g., undersulfated (30, 40, 56, 
63), or structurally altered, e.g., keratan sulfate glycosamin- 
oglycan chains (39,  44).  Such modified proteoglycans may 
account for the fact that transformed ceils fail to assemble a 
pericellular matrix as compared with their normal counter- 
parts (16, 21, 25, 57, 58). 
Recent  studies  using  several  different  mAb's  have 
identified a CSPG associated with human malignant mela- 
noma.  These  molecules  are  believed  to  play  a  role  in 
cell-cell interactions and may be important in growth regula- 
tion (6,  7,  22,  49,  61,  62,  Yang,  H.  M.,  U.  S.  Garrigues, 
K. E.  Hellstr6m,  S.  Hakomori,  and I.  Hellstr6m,  manu- 
script  submitted  for  publication).  Two  mAb's  (48.7  and 
F24.47) that recognize an epitope on either the core glyco- 
protein or the intact proteoglycan have been used to purify 
these  melanoma-associated  antigens.  Thus,  we  have pro- 
posed a model for the structure of the CSPG based on bio- 
chemical analyses. Furthermore, we have used the antibod- 
ies to localize the core glycoprotein and the proteoglycan 
antigens at the ultrastructural level and report, for the first 
time,  that  they  are  present  primarily  on  microspikes,  a 
microdomain of  the cell surface that is involved in cell attach- 
ment and cell-cell interactions. 
Materials and Methods 
Materials 
Materials were purchased from the following sources: RPMI-1640  medium 
and anti-pleuropneumonia-like organisms agent from Gibco, Grand Island, 
NY; defined FBS serum from HyClone Laboratories, Sterile Systems, Inc., 
Logan, UT; tissue culture roller bottles from Coming Glass Works, Corning 
Science Products, Coming, NY; gold (5 nm)-labeled goat anti-mouse IgG 
from E. Y. Laboratories, Inc., San Mateo, CA; gold (40 nm)-labeled goat 
anti-mouse IgG from Janssen Pharmaceutica, Piscataway,  NJ; vinyl micro- 
titer plates from Costar, Data Packaging Corp., Cambridge, MA; EPON 812 
from Ted Pella, Inc., Irvine, CA; carrier-free [35S]sulfate (379 mCi/mmol), 
D-[6-3H]glucosamine  (39  Ci/mmol),  [3~Slmethionine  (>800  Ci/mmol), 
and EN3HANCE from New England Nuclear, Boston, MA; NP-40 from 
Particle Data, Inc., Elmhurst, IL; benzamidine hydrochloride, 6-aminohex- 
anoic acid, and XAR-5 film from Eastman Kodak Co., Rochester, N.Y.; 
phenylmethylsulfonyl fluoride PMSF, N-ethylmaleimide and diethylamine 
from Sigma Chemical Co., St. Louis, MO; EDTA from MC&B Manufac- 
turing  Chemists,  Inc.,  Gibbstown,  NJ;  Affi-Gel  10  and  ~4C-labeled 
molecular  mass  markers  from  Bio-Rad  Laboratories,  Richmond,  CA; 
DEAE-Sephacel,  Sepharose  CL-4B,  and  CL-6B  from  Pharmacia  Fine 
Chemicals,  Piscataway,  NJ;  NaBH4  from  Wilshire  Chemical  Co.  Inc., 
Gardena, CA; chondmitinase AC and ABC from Miles Laboratories, Inc., 
Elkhart, IN; mouse myeloma PI.17 from American Type Culture Collec- 
tion, Rockville, MD; and Hep-212 well teflon slides from Meloy Laborato- 
1. Abbreviations used in this paper:  CSPG, chondroitin sulfate proteogly- 
can; TNEN,  buffer consisting of Tris-HCI, NaCI,  EDTA, and NP-40. 
ries, Inc., Springfield, VA. Digitizer was a 4052 graphics system computer 
and  4956  graphics tablet  from Tektronix,  Inc.,  Beaverton,  OR;  rabbit 
anti-mouse Ig from Calbiochem-Behring Corp., La Jolla, CA; Immuno- 
Precipitin (formalin-fixed Staphylococcus  aureus) from Bethesda Research 
Laboratories, Gaithersburg, MD. 
Cells and Culture Conditions 
The  cell  line  M  2669-C1  13  was  established  by  explanting  a  human 
metastatic melanoma (4) and M 1477 was obtained from the Sloan-Kettering 
Institute for Cancer Research, New York, NY (12). Cells were maintained 
in RPMI-1640  medium supplemented with 15 % inactive FBS, 1% penicillin 
and streptomycin, 1% nonessential amino acids,  1 mM sodium pyruvate, 
2  mM L-glutamine, and  1%  anti-pleuropneumonia-like organisms agent, 
and buffered with NaHCO3.  Cultures were grown to ,~50% confluency at 
37°C in a  humidified atmosphere containing 5%  CO2 (68).  The M  1477 
cell  line  was  tested  for,  and  shown  to  be  free  of  contamination  by 
Mycoplasma,  however, the status of M 2669-CI  13 was not known at the 
time of these experiments. 
Antibodies 
Two mAb's, 48.7 (22) and F24.47, were used as the primary probes for the 
localization and biochemical characterization studies. We have previously 
reported that mAb 48.7 is an IgG 1 that has a high degree of specificity for 
human melanomas and compound nevi, while normal tissues and other 
tumors either express none or very low levels of the antigen (22).  mAb 
F24.47 is an IgG 2b that recognizes a different epitope on the antigen defined 
by mAb 48.7. This epitope has been referred to as PG  a (Yang, H. M., U. S. 
Garrigues, K. E. Hellstr6m, S.  Hakomori, and I.  Hellstr6m, manuscript 
submitted for publication).  An IgG 2a  immunoglobulin secreted by the 
mouse myeloma Pl.17 was used as a negative control antibody. For the im- 
munocytochemical studies, an indirect staining protocol was used in which 
the secondary antibody, goat anti-mouse IgG,  was conjugated to either 40 
nm or 5 nm colloidal gold. 
A n tigen Purification 
M 2669-C1  13 and M  1477 melanoma cells were grown to 50% confluency 
in 850 cm  2 roller bottles in RPMI medium that contained 50-75  p.Ci/ml 
[35S]sulfate and l0 p,  Ci/ml [3Hlglucosamine, or 50 ~tCi/ml [35S]methionine 
and  l0 IzCi/ml  [3H]glucosamine.  After 48 h of labeling, the medium was 
aspirated and the cells rinsed three times with warm (37°C) PBS, pH 7.2. 
The adherent cells were then released from the substratum by treatment with 
0.5  mM EDTA,  resuspended and washed three times in  RPMI medium 
using repeated centrifugation (400 g). The pellet was resuspended in 20 mM 
Tris-HCI buffer, pH 8.0, containing 100 mM NaCl, 1 mM EDTA, and 0.5% 
NP-40 (referred to TNEN buffer) for 30 min at 4°C. The TNEN buffer also 
contained the  following protease inhibitors: 0.05  M  benzamidine hydro- 
chloride, 0.16 M 6-aminohexanoic acid,  1 mM PMSF and l0 mM N-ethyl- 
maleimide. The cell lysate was recentrifuged at 1,700 g to remove debris and 
the superuatant collected and centrifuged at 45,700 g for 30 min at 4°C. The 
supernatant was isolated and stored at  -70°C for further analysis, and is 
referred to as the cell lysate. 
The  antigenic determinants defined by  mAb's 48.7  and  F24.47  were 
purified by affinity chromatography (24, 45, 49). The affinity columns were 
prepared by coupling 20  mg of normal mouse IgG,  mAb 48.7, or mAb 
F24.47 to 1.0 ml of Affi-Gel 10.  Cell lysates were sequentially applied to 
three columns consisting of 0.5  ml of Sepharose CL-4B,  0.5  ml normal 
mouse IgG Affi-Gel, and 0.5 ml mAb 48.7 Affi-Gel, respectively, in TNEN 
buffer at a flow rate of 2 ml/h. The first two columns were used to eliminate 
any debris or molecules that might stick nonspecifically to mAb 48.7 Affi- 
Gel column. The mAb 48.7 or t724.47 affinity columns were washed in four 
antigen  from  M  2669-C1  13;  (b)  mAb  F24.47  affinity-purified antigen  from  M  1477.  The  Vo  and  Vt positions  were  identified  using 
[3H]DNA and [3SS]sulfate, respectively. Analysis by SDS PAGE (7.5%  gel) resolved the mAb 48.7-defined antigen into a  high molecular 
mass component >400,000  D, a  250,000-D  component,  and a  52,000-D  component (SDS  PAGE inset, lane 1).  The antigen was chro- 
matographe  d  on DEAE-Sephacel and a  portion that did not bind to the column was recovered as the DEAE-nonbinding fraction (lane 
2). This fraction had an identical elution profile as peak II when analyzed by gel filtration chromatography (data not shown). The remainder 
of the sample bound to the column and was eluted with 0.8 M  NaC1/TNEN  buffer as the DEAE-binding fraction (lane 3).  This fraction 
also had an identical elution profile as peak I when analyzed by gel filtration chromatography (data not shown). Molecular mass determina- 
tions are based on protein molecular mass marker standards:  myosin (200 kD),  phosphorylase B  (92 kD),  BSA (69 kD),  ovalbumin (46 
kD),  and [¢t1(III)]3  collagen (291  kD). 
Garrigues  et al.  Characterization of a Cell Surface Proteoglycan  1701 Figure 2. Proteoglycan analysis of peak I from M 2669-C1 13 melanoma cells. A control aliquot of the [35S]sulfate- and pH]glucosamine- 
labeled peak I isolated as the DEAE-binding fraction (see legend for Fig.  1) was handled as a control (a), digested chondroitinase ABC 
(b), or treated with alkaline borohydride (c). All samples were brought to 0.2% SDS and chromatographed on identical Sepharose CL-6B 
colunms. Arrow (b) indicates the elution position of a collagen standard [~tl(III)3] that has a  molecular mass of 291,000  D.  The  Iio and 
Vt positions were identified as described in the legend to Fig.  1. Core protein analysis by SDS PAGE. M  2669-C1  13 cells were labeled 
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40; (c) with 1.5 mi TNE +  0.1% NP-40; and (d) with 2.5 ml TNE +  0.2% 
NP-40  (49).  The  afffinity-purified  antigens  were  then  eluted  from  the 
columns with 5 ml of  0.1 M diethylamine, pH 11.5, and immediately brought 
to neutral pH. Using this technique, it was possible to isolate "o3.3 % of the 
total [3~S]sulfate-labeled  macromolecules incorporated into the cell lysate. 
For  further purification,  the  antigen that  eluted  from the mAb 48.7 
column was applied to a 0.2-ml DEAE-Sephacel column equilibrated with 
TNEN buffer.  The nonbinding fraction was collected at a flow rate of 1 
ml/h. After extensive washing, the DEAE-binding fraction was eluted by 
resuspending the resin in 0.4 ml of TNEN buffer containing 0.8 M  NaCI 
for 1-2 h. The DEAE-binding and -nonbinding fractions were subsequently 
analyzed by SDS PAGE and gel filtration chromatography (see below). 
Immunoprecipitation and Electrophoresis 
The  [35S]methionine/[3H]glucosamine-labeled  DEAE-binding  fraction 
was immunoprecipitated as previously described (64). Briefly,  the antigen 
fraction was preadsorbed with rabbit anti-mouse IgG (2% vol/vol) and fixed 
and heat-killed S.  aureus (2 % wt/vol).  10 gg of mAb 48.7 were then in- 
cubated with ,x,l.2  x  105 clam of preadsorbed antigen. Rabbit anti-mouse 
IgG was then added to the incubation mixture and the immune complexes 
were adsorbed to 1 mg of S. aureus. The immune complexes were washed 
three times in TNEN buffer that was supplemented with 10 mM sodium io- 
dide, 10 mM sodium deoxycholate, 2% BSA, and 0.2% SDS, and washed 
once in TNEN (diluted 1:10 in H20). The pellets were then suspended in 
100 I.tl of reducing Laemmli sample buffer (containing 2-mercaptoethanol) 
and boiled for 3 rain. The bacteria were removed by centrifugation and the 
supernatant containing the immunoprecipitated antigen was analyzed by 
electrophoresis on 7.5%  SDS polyacrylamide gels (36).  In some experi- 
ments,  [35S]sulfate/[3H]glucosamine-labeled affinity-purified antigen and 
DEAE-binding or -nonbinding fractions were analyzed by SDS PAGE that 
had not been immunoprecipitated. 
Gel Filtration  Chromatography 
To further analyze the molecular size of the melanoma antigen, aliquots of 
the affinity-purified material or the DEAE-binding fractions were analyzed 
by gel filtration chromatography. The columns used included: Sepharose 
CL-4B (0.7 x  100 cm) equilibrated with TNEN buffer and eluted with flow 
rate of 2.5 ml/h; and Sepharose CL-6B (0.7  x  100 cm) equilibrated with 
0.2% SDS in 0.15 M sodium acetate, 1 mM CaCl, pH 7.4, and eluted with 
flow rate of 1.5 ml/h. Fractions (0.75 ml) were collected and assayed for ra- 
dioactivity by scintillation counting; column yields were 85-95 %. 
Pro  teoglycan A nalysis 
To identify the proteoglycan nature of the DEAE-binding fraction, the frac- 
tion was digested with chondroitinase ABC or AC II (51). Enzymatic diges- 
tion was carried out by diluting 60 I11 of the sample in an equal volume of 
digestion buffer containing 0.3 U of enzyme in 0.5 M Tris-HC1,  0.36 M so- 
dium acetate, and 0.1% BSA, pH 6.8. The buffer also contained the following 
protease inhibitors: 10 gM EDTA, 10 gM N-ethylmaleimide, 5 gM PMSE 
and 0.36 mM pepstatin. The samples were incubated at 37°C for 4 h, after 
which they were brought to 0.2% in SDS and analyzed on a Sepharose CL- 
6B (0.7 x  100 cm) column. Control samples were handled identically except 
that no enzyme was added. To determine the size of the core glycoprotein, 
the DEAE-binding fraction was immunoprecipitated with mAb 48.7 and S. 
aureus and digested by resuspending the washed precipitates bound to S. 
aureus in 50 Ixl cbondroitinase ABC digestion buffer and incubated at 37°C 
for 4  h. The core glycoproteins were then analyzed by SDS PAGE. 
To study the glycosaminoglycan chains of the proteoglycan, the DEAE- 
binding fraction that was isolated from M 2669-C1  13 cells and labeled with 
[35S]sulfate and [3H]glucosamine was treated with  1 M  NaBI-h in 0.1  M 
NaOH for 18 h at 45°C (8). The reaction mixture was then neutralized with 
acetic acid and the glycosaminoglycan chains and oligosaccharides released 
from the core protein were analyzed by gel filtration chromatography on 
Sepharose CL-6B eluted with TNEN. 
Immunoelectron Microscopy 
Single cell suspensions of M  1477 were prepared by trypsinization and 
plated at a concentration of I  x  104 cells/well in vinyl micmtiter plates or 
1.5  x  103 cells/well on well teflon slides (Meloy Laboratories, Inc.). After 
a 24-48-h incubation, the cells were washed three times in warm (37°C) 
PBS, pH 7.2, and fixed for 2 h in warm fixative (0.5% paraformaldehyde 
and 0.65%  glutaraldehyde) diluted in 0.1 M sodium cacodylate buffer, pH 
7.4  (28).  After fixation the cells were washed three times in cacodylate 
buffer and used for ultrastmctural immunocytochemistry, either directly or 
after storage at 4°C. 
rnAb's  48.7 and F24.47 were isolated from hybridoma culture supernatant 
(10 gg/ml of antibody) or were purified from ascites fluid using Protein 
A-Sepharose. All antibodies were added to a diluent that contained 10% 
normal human serum and 3 % normal goat serum in PBS. The hybridoma 
culture supernatants were diluted 1:1, while affinity-purified  antibodies were 
diluted to 10-25  ltg/ml. The 5-nm and 40-nm gold-labeled secondary anti- 
bodies were diluted to final concentrations of 2.7 and 2.5  I.tg/ml, respec- 
tively. 
The immunogold staining procedure consisted of an initial preincubation 
of the fixed cells with normal human serum (diluted 1:5 in PBS) for 30 min 
at room temperature to reduce nonspecific background staining. The serum 
was then aspirated and replaced with mAb 48.7 or F24.47.  After a 4-h incu- 
bation at room temperature, the primary antibody was removed and the cells 
were washed three times for 10 min in an agitated PBS bath. The secondary 
antibody, a goat anti-mouse IgG (conjugated to 40 nm gold for whole-eell 
mounts or 5 um gold for thin sections) was incubated with the cells for 2-3 
h. The cells were then washed as above, treated with 1% OsO4 for 30 min 
and postfixed with 2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 
M sodium eacodylate buffer. The fixed cells were dehydrate with graded eth- 
anol and infiltrated with Epon 812 or dried at the critical point of CO2. 
Thin sections of embedded cells were cut on an Ultratrome HI (LKB Instru- 
ments, Inc., Gaithersburg, MD), collected on Formvar-coated grids, and 
double stained with uranyl acetate and lead citrate. Dried specimens to be 
used for wbole-mount microscopy were coated with carbon and replicas 
were subsequently floated onto H2O and picked up on coated copper grids. 
All specimens were examined with an electron microscope (model 100 B; 
JEOL USA, Peabody, MA) at an accelerating voltage of 60 kV for the sec- 
tioned specimens and 1130 kV for the whole-mount preparations. 
The localization of the antigen defined by mAb 48.7 to specific cell sur- 
face structures was quantitated using transmission electron microscopy. The 
topographical features of M  1477 cells were divided into three groups that 
included microspikes, surface blebs, and underlying areas of smooth mem- 
brane (13, 60). Micrographs of immunogold-stained cells taken at the same 
magnification were used to generate the membrane length data. Measure- 
ment of the membrane lengths for each of the three groups was determined 
using a graphics tablet system computer (Tektronix, Inc.). The mean num- 
ber of gold particles per micrometer of membrane per group was deter- 
mined. The difference between the groups was compared by the Student's 
t test. 
Results 
mAb's 4&7 and F24.47 Recognize Two Different 
Epitopes on the Melanoma-associated CSPG Antigen 
The antigens recognized by mAb's 48.7  and F24.47  were 
purified from detergent-solubilized cell extracts of M 2669- 
C1 13 and M  1477 melanoma cells by affinity chromatogra- 
phy. The mAb 48.7-defined antigen from M 2669-C1 13 cells 
that had been labeled with [35S]sulfate and [3H]glucosamine 
was resolved into two major peaks of radioactivity when ana- 
lyzed  by  Sepharose  CL-4B  chromatography,  namely,  a 
double-labeled 35S/3H peak (peak I) that eluted at a Kay = 
0.3 and a single-labeled 3H peak (peak II) that eluted at Kay 
with [35S]methionine and [3H]glucosamine. Peak I was isolated and then immunoprecipitated with rnAb 48.7 and analyzed by SDS PAGE 
(7.5%  gel).  Lane 1,  immunoprecipitated peak I; lane 2,  immunoprecipitated peak I  digested with chondroitinase ABC.  Molecular mass 
determinations are based on protein molecular mass marker standards as described in Fig.  1. 
Garrigues  et al.  Characterization  of a  Cell Surface Proteoglycan  1703 Figure 3. Cell surface topography of M  1477 melanoma. Cells were prepared for scanning electron microscopy (a and b) or as whole-cell 
mounts for transmission electron microscopy (c). The topography of M  1477  (for overview see a) was characterized by numerous upper 
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purified on a mAb F24.47 affinity column resulted in the iso- 
lation of only peak I, while the glycoprotein peak (peak II) 
was absent (Fig.  1 b). Previously, immunoprecipitation data 
using mAb 48.7 and M  1477 cell lysates demonstrated that 
these cells do express the glycoprotein component on the cell 
surface (22).  The results presented here indicate that this 
glycoprotein component, however, is not recognized by mAb 
F24.47.  Further studies demonstrated that peak I could be 
separated  from peak II by DEAE-Sephacel ion exchange 
chromatography.  Approximately  50%  of the  [3H]glucos- 
amine-labeled  material  and  all  of the  [35S]sulfate-labeled 
material bound to the ion exchange resin and could be eluted 
with a high salt (0.8 M NaC1)-containing buffer. The DEAE- 
binding fraction contained only a high molecular mass com- 
ponent (Fig.  1, SDS PAGE inset, lane 3) that coeluted with 
peak I when analyzed by gel filtration chromatography (data 
not shown). A comparison of the elution position of peak I 
with that reported for other proteoglycans indicates that peak 
I had an approximate molecular mass of 420,000 D (19, 42). 
The material which did not bind to the ion exchange resin 
was labeled only with [3H]glucosamine and it coeluted with 
peak II when analyzed by gel filtration (data not shown). 
Analysis of  the DEAE-nonbinding fraction by SDS PAGE in- 
dicated that it contained 250,000-D and 52,000-D compo- 
nents (Fig. 1, SDS PAGE inset, lane 2). The material migrat- 
ing  at  52,000  D  most  likely  represented  a  component 
adsorbing  nonspecifically to the  affinity column,  since  it 
could  not be  immunoprecipitated from an  aliquot of the 
affinity-purified antigen using mAb 48.7. 
The fact that peak I labeled with [aSS]sulfate and [3H]glu- 
cosamine and bound to a DEAE-Sephacel column suggested 
that it was a proteoglycan. To investigate this further, an ali- 
quot of the [35S]sulfate- and [3H]glucosamine-labeled peak I 
(purified on a mAb 48.7 column) from M 2669-C1  13 cells 
was digested with either chondroitinase ABC (Fig. 2) or AC 
II (data not shown) and the digestion products separated by 
gel filtration on Sepharose CL-6B. An aliquot representing 
the untreated control eluted as a single peak in the void vol- 
ume of the Sepharose CL-6B column (Fig. 2 a). After diges- 
tion  with  either  enzyme,  all  of the  [35S]sulfate  activity 
eluted  at  the  column  total  volume,  indicating  that  the 
glycosaminoglycan  chains  were  completely  degraded  by 
both enzymes (Fig. 2 b). A small peak of [3H]glucosamine- 
labeled material eluted at a Kay =  0.38 and presumably rep- 
resented the core protein that contained oligosaccharide side 
chains.  Chondroitinase  digests  of [35S]methionine-labeled 
peak I also eluted at this position (data not shown). A colla- 
gen standard,  [(II(]]I)]3, having a molecular mass of 291,000 
D, eluted slightly before the core glycoprotein peak (see ar- 
row, Fig. 2 b). To obtain a better estimate of the size of the 
core  glycoprotein,  an  aliquot  of  peak  I  (labeled  with 
[35S]methionine  and [3H]glucosamine) was immunoprecipi- 
tated with mAb 48.7, digested with chondroitinase ABC and 
analyzed by SDS PAGE (Fig.  2 b,  SDS PAGE inset).  The 
nondigested fraction barely entered the 7.5% gel (lane 1). 
After chondroitinase ABC digestion, the radiolabeled band 
shifted to a position corresponding to 250,000 D  (lane 2). 
This position is identical to that of  peak II (Fig. 1, SDS PAGE 
inset, lane 2). This indicates that the 250,000-D component 
isolated as the DEAE-nonbinding fraction and the core gly- 
coprotein of the CSPG are probably the same molecule. Pep- 
tide map analyses are consistent with the conclusion that the 
250,000-D components and the core glycoprotein are similar 
(7,  49,  62).  These data  also  demonstrate  that  mAb  48.7 
recognizes an epitope present on the core glycoprotein as 
well as on the intact CSPG, while the epitope defined by mAb 
F24.47 is present only on the proteoglycan. Epitope analysis 
using mAb F24.47  suggests that the determinant contains 
galactose (Yang, H. M., U. S. Garrigues, K. E. HellstrOm, 
S.  Hakomori, and I.  Hellstrtm, manuscript submitted for 
publication). 
To determine the size of the glycosaminoglycan chains, an 
aliquot of the double-labeled peak I isolated from M 2669-C1 
13 and purified on a mAb 48.7 column was treated with alka- 
line borohydride to release glycosaminoglycan and oligosac- 
charide chains (8). The glycosaminoglycan chains that were 
labeled with both [35S]sulfate and [3H]g!ucosamine (peak 1) 
eluted at a Kay =  0.29 when chromatographed on Sepharose 
CL-6B (Fig. 2 c). The glycopeptide/oligosaccharide fraction 
that labeled only with [3H]glucosamine (peak 2) eluted at a 
Kay  =  0.91.  By comparison to a  standard curve for chon- 
droitin sulfate samples of known molecular mass, the elution 
position of peak 1 corresponds to an approximate molecular 
mass of 60,000 D  (59). The data also indicate that 58 % of 
the [3H]glucosamine radioactivity was incorporated into the 
glycosaminoglycan chains of peak 1.  The remainder of the 
radioactivity  released  by  alkaline  borohydride  treatment 
eluted in a position corresponding to oligosaccharide (9). 
The majority  (88%)  of the oligosaccharides were labeled 
with [3H]mannose, suggesting that they are attached to the 
core  protein  through  N-linkage  to  asparagine  (data  not 
shown). 
Ultrastructural Immunocytochemistry: the 
Melanoma-associated CSPG is Localized to a Specific 
Microdomain of the Cell Surface 
The morphology of M  1477 melanoma cells was examined 
by scanning electron microscopy. Although there were large 
variations in cell shape and size, as would be expected from 
a rapidly dividing tumor cell line, typical cell surface fea- 
tures are illustrated in Fig. 3. At the periphery, M  1477 cells 
characteristically sent  out delicate,  finger-like projections 
that made contact with the substratum (Fig. 3 a). In densely 
populated cultures where cell-cell interactions were occur- 
ring, these processes were often involved in the initial events 
of cell-cell contact (Fig.  3 b).  On the upper cell surface, 
cell surface projections or microspikes (M), blebs (B), and areas of smooth membrane (S) (a and b). Microspikes were also present at 
the cell margin and were shown to be involved in the initial events of cell-cell contact (b) as well as cell-substratum contact (a-c). The 
high resolution transmission electron micrography (c) clearly shows the upper surface microspikes as distinct structures; however, blebs 
were not so easily identified in these preparations. Three regions of the cell have been examined for the expression of the melanoma CSPG 
(see Fig. 4) namely, the upper cell surface (box A), the cell margin (box B), and cell-substratum  attachment sites (box C). Bar, (a and 
b)  10 I~m; (c) 1 Ima. 
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of smooth membrane (Fig.  3 a  and b). To examine the cell 
surface in more detail, whole-cell mounts were prepared for 
transmission electron microscopy. Numerous  1-2-1xm pro- 
jections, which we refer to as microspikes, were easily dis- 
tinguished from areas of smooth membrane on the upper cell 
surface (Fig. 3 c and Fig. 4). At the cell periphery, projec- 
tions with a similar diameter ('080 nm) as microspikes were 
observed (Fig. 3 c and Fig. 4). These peripheral microspikes 
were generally much longer (up to 20 p.m) than the upper 
surface structures  and  they  formed complex footpads that 
were intimately associated with the substratum (Fig. 3 c and 
Fig. 4, d, e, and f). Bleb structures were more difficult to 
identify in these preparations; however, their presence was 
confirmed using thin sections (Fig. 5). To delineate the over- 
all distribution of the proteoglycan defined by mAb F24.47, 
M  1477 melanoma cells  were  labeled  by an  indirect  im- 
munogold technique and prepared for whole-mount micros- 
copy. Three areas of the cell surface were examined as shown 
in Fig.  3 c: (A) the upper surface, (B) the cell margin, and 
(C) cell-substratum contact points.  The melanoma-associ- 
ated CSPG antigen defined by mAb F24.47  was shown to 
have a restricted distribution and was localized predominant- 
ly to microspikes on the upper cell surface (Fig. 4 a). Simi- 
larly,  peripheral  microspike structures  radiating  from the 
cell margin were shown to express this antigen (Fig. 4 c). It 
was  often  noted  that  these  structures  usually  formed 
branches after the microspike had extended ,05 gm from the 
cell margin.  At these branch points,  cellular material was 
layed down in the form of a footpad that made contact with 
the substratum.  As shown in Fig.  4  e, these footpad struc- 
tures also contain the melanoma-associated antigen. Control 
experiments  were  performed  in  which  mAb  F24.47  was 
replaced  with  an  isotype-matched  antibody  secreted  by 
mouse myeloma Pl.17. Essentially no labeling of the M  1477 
cells was observed (Fig.  4, b, d, and f). 
To examine the cell surface in more detail and to assess 
whether  both  the  core  glycoprotein  and  the  CSPG  were 
localized to microspikes, melanoma cells were labeled using 
mAb 48.7, thin sectioned, and analyzed by transmission elec- 
tron microscopy. The general topographical features of sec- 
tioned  M  1477 cells were similar to those seen by whole- 
mount  microscopy,  except  that  surface  blebs  were  more 
discernible in the sections. The immunolocalization results 
were also in agreement and showed that the antigen defined 
by mAb 48.7 was predominantly associated with the micro- 
spikes, while the blebs and underlying smooth cell surfaces 
were stained considerably less (Fig. 5). Also, the gold parti- 
cles tended to be associated with an amorphous surface ma- 
terial and frequently occurred in clusters (Fig. 5 a). Further 
support  for  the  specific  localization  of  the  antigen  to 
microspikes was obtained by quantitating the number of la- 
beled particles per micrometer of membrane length of either 
blebs, microspikes, or underlying cell surface. There were 
39.5 particles/txm of microspike membrane compared with 
0.35  and  2.9  particles/~tm of bleb  or underlying  surface, 
respectively  (Fig.  6);  the  first  of these  three  groups  was 
statistically significant from the other two (P <  0.001). 
Discussion 
The antigen recognized by mAb 48.7 is expressed primarily 
on melanomas and benign nevi (22) and is similar (identi- 
cal?) to an antigen first described by Bumol and Reisfeld (6) 
and subsequently by others (7, 49, 61, 62; Yang, H. M., U.  S. 
Garrigues, K. E. Hellstr6m, S. Hakomori, and I. HellstrOm, 
manuscript submitted for publication). Ross et al. have pro- 
posed that this antigen consists of two core glycoproteins as- 
sociated to form a homodimer of 520,000 D, and, that after 
the addition of glycosaminoglycan chains (30,000 D each), 
the completed proteoglycan had an estimated size of 7-10  × 
105 D (49). Our results, using gel filtration chromatography 
under nondenaturing conditions, demonstrated that the core 
glycoprotein eluted in a slightly retarded position relative to 
a collagen standard (291,000  D) and had a molecular mass 
of 250,000 D when analyzed by SDS PAGE. The proteogly- 
can eluted at a Kav of 0.3 on Sepharose CL-4B, which gives 
an estimated molecular mass of 420,000 D, similar to the size 
of a CSPG isolated from chick embryo cartilage (42). Since 
the size of the glycosaminoglycan chains was estimated to be 
"060,000  D by gel filtration chromatography, the addition of 
three glycosaminoglycan chains would account for the shift 
in molecular mass. It is not clear why our results differ from 
those of Ross et al. (49).  It is possible the differences could 
be attributed to the different melanoma cell lines used, even 
though we have generated identical results using two differ- 
ent melanoma cell lines. It is probably not due to a difference 
in  mAb's, since an antibody from Bumol and  Reisfeld (6) 
recognizes the antigen defined by mAb 48.7 (Mosely, G. H., 
unpublished  data)  as well as that described by Ross et al. 
(49). 
We do not yet know how the melanoma CSPG is associated 
with the cell surface. Three pieces of data suggest, however, 
that the core protein of the CSPG is membrane-associated 
and may be intercalated in the plasma membrane. First, Wil- 
son et ai. (62) have shown that the CSPG can be extracted 
from cells three times more effectively with buffer that con- 
tains detergent than with high or low salt buffers. Second, the 
proteoglycan can be extracted from cells with 4 M guanidine 
hydrochloride as large aggregates that can be dissociated in 
the presence of detergent (38,  41;  Garrigues, H. J., unpub- 
lished observation). Third, when melanoma cells in culture 
were treated with mAb F24.47, there was a redistribution of 
the CSPG antigen at the cell surface (Garrigues, H. J., un- 
Figure 4.  Immunogold-labeled whole-cell mount of M 1477 melanoma ceils. The cells were fixed with 0.5 % paraformaldehyde and 0.6% 
glutaraldehyde and labeled using mAb F24.47 as the primary probe, followed by goat anti-mouse IgG conjugated to 40 nm colloidal gold 
as the secondary antibody. Three areas of the cell surface (equivalent to boxes A, B, and C of Fig. 3 c) were studied. On the upper cell 
surface, mAb F24.47 was localized almost exclusively to short (1-2 ~tm)  microspike processes (a). Areas of smooth membrane were labeled 
much less. At the cell margin, longer (up to 20 lam) peripheral microspikes (c) as well as distant footpads (e) were shown to be enriched 
for the melanoma CSPG. Control experiments where mAb F24.47 was replaced by mAb Pl.17 showed only occasional gold particles as- 
sociated with corresponding  areas of the cell surface (b, d, and f). M, microspike; S, smooth membrane surface;  open arrow, footpad; 
small arrow, nonspecific label in d.  Bar (a-d)  1 Inn, (e and f) 0.5 Ixm. 
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tation.  Membrane lengths for 
blebs  (group  1),  underlying 
smooth surface (group 2) and 
microspikes  (group  3)  were 
determined from electron mi- 
crographs  of  ilnmunogold- 
labeled M  1477 cells (see Fig. 
5). The mean number of gold 
particles per micrometer mem- 
brane +  SEM was calculated and the groups were compared by Stu- 
dent's t test. The t value for group 1 (n  =  16) vs. group 3 (n  =  18) 
=  6.46 (P < 0.001) and comparing group 2 (n =  23) vs. 3, t  =  7.18 
(P <  0.001). 
published observation).  Fourth,  the ultrastructural  data ob- 
tained in this study demonstrates that the CSPG is localized 
to microspikes,  which constitute a  specific microdomain of 
the cell surface. We have examined both whole-mount prepa- 
rations and sections of cells labeled by the immunogold tech- 
nique.  In  sections,  the  melanoma  CSPG  antigen  was  as- 
sociated with an amorphous  material that was observed on 
projections of the cell surface, and the antigen was often seen 
in clusters.  The sectioned material,  however, provided little 
information about the organization of these projections rela- 
tive to the entire cell surface, nor was it possible to section 
remote cell attachment sites and accurately determine their 
orientation to the cell body. We therefore chose to study the 
localization of the CSPG antigen using whole-mount prepa- 
rations where the orientation of surface domains is more eas- 
ily interpreted.  The results were identical  for immunogold- 
labeled cells prepared by either procedure and demonstrated 
that the melanoma CSPG antigen is expressed almost exclu- 
sively on  microspike projections  located on  the upper cell 
surface as well as radiating from the cell margin. This study 
also  indicates  that  mAb 48.7  recognizes  an  epitope  on  the 
core  glycoprotein  and  the  intact  CSPG.  Both  of  these 
molecules are present on the cell  surface since they can be 
iodinated  by the lactoperoxidase  procedure  (22).  Autoradi- 
ography  of  the  immunoprecipitated  antigens  analyzed  by 
SDS PAGE also indicated that they were present on the cell 
surface at an approximate molar ratio of 1:1  (22).  It was not 
known, however, whether the proteoglycan and the core pro- 
tein were localized to the same structure at the cell surface. 
Using mAb 48.7 and another antibody, mAb F24.47,  which 
defines  an epitope present only on  the intact proteoglycan, 
we found identical  staining  patterns of the cell surface,  im- 
plying that the core glycoprotein and the proteoglycan have 
the same restricted distribution on microspikes. This finding 
suggests that, for the melanoma-associated proteoglycan, the 
glycosaminoglycan chains probably do not play a role in de- 
termining  its ultimate destination  at the cell  surface. 
The functional  significance of the specific localization  of 
the  melanoma-associated  CSPG  antigen  to  microspikes  is 
unknown.  Studies  on  cell  motility  have demonstrated  that 
migrating cells send out microspikes that make initial contact 
with the substratum or with adjacent cells (1).  For example, 
when nontransformed 3T3 cells come into contact with each 
other, which is a process mediated by microspikes, the cells 
move apart,  that is, they are contact inhibited  (2),  while tu- 
mor cells,  which also have microspikes,  are not contact in- 
hibited.  One  possible  interpretation  of  this  is  that  the 
microspikes  are  somehow  altered  in transformed  cells  and 
the presence of tumor-associated CSPG might play a role in 
this  alteration.  Treatment  of melanoma cells  with  an  anti- 
body to the CSPG antigen can block the early events of cell 
spreading  on  a  basement  membrane  synthesized  by  en- 
dothelial  cells  (7),  and  can  specifically  inhibit  anchorage- 
independent  growth  of  melanoma  cells  in  soft  agar  (17). 
These  data  suggest  that  the  tumor-associated  CSPG  may 
mediate cell attachment  and  contact  inhibition  and  may be 
an important potentiator  of the metastatic  process. 
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